Premium
The sevoflurane saving capacity of a new anaesthetic agent conserving device compared with a low flow circle system
Author(s) -
Enlund M.,
Lambert H.,
Wiklund L.
Publication year - 2002
Publication title -
acta anaesthesiologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.738
H-Index - 107
eISSN - 1399-6576
pISSN - 0001-5172
DOI - 10.1034/j.1399-6576.2002.460506.x
Subject(s) - fresh gas flow , sevoflurane , medicine , anesthesia , remifentanil , mann–whitney u test , propofol
Background: An anaesthetic agent conserving device (ACD) has been added to a Bain system to approach the agent‐saving capacity of a low flow circle system. Methods: Randomly selected ASA physical status I patients received a standardized anaesthetic with sevoflurane in air/O 2 through either a circle system with 1.5 l/min fresh gas flow ( n = 8), or through a Bain system with an added ACD with fresh gas flow 4.4–6.4 l/min ( n = 8). A target controlled infusion of remifentanil was used for analgesia. Results: The median sevoflurane consumption was 19.7 and 22.0 ml/MAC/h with the low flow circle system and the Bain system + ACD, respectively ( P =0.10, Mann–Whitney U ‐test), or when adjusted for weight 0.25 and 0.28 ml/MAC/h/kg ( P =0.26, Mann–Whitney U ‐test). Conclusion: The expenditure of sevoflurane with a Bain system + ACD was close to that in a circle system with 1.5 l/min fresh gas flow. It is thereby possible to use sevoflurane to all its potential, performing for example rapid alterations in end‐tidal concentration using high fresh gas flows by combining a Bain system with an ACD. Although the price is not decided for this not yet commercially available device, a potential for a lower cost exists. Additionally, there will be no concerns of toxic compounds produced in the absorber.